Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | EVP, Chief Scientific Ofc, COO | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 145,435 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 18,000 · Balance 163,435 Row 2 · 2026-10-05 · Sale · Disposed 18,000 · Balance 145,435 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2030-04-17 | Direct | 46,398 |
Reported balance
After 2026-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-05 · Exercise / conversion · Disposed 18,000 · Balance 46,398 F2: Stock Option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
F2: Stock Option is fully vested and exercisable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Icosavax, Inc.
Report date February 19, 2024 · Filed February 21, 2024
Section 16 reporting ended · disclosed 2024-02-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-02-19 · Other · Disposed 3,695 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-02-19 · Disposition to issuer · Disposed 7,392 · Balance 0 F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.25 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-19 · Disposition to issuer · Disposed 44,556 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.89 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-19 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2025 Filed Mar 4, 2025 02:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,362 | $5.35 | $28,686.70 |
DisclosureSEC source: 0001649094-25-000039 · wk-form4_1741054462.xml · nonDerivative · entry 6 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 02:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,638 | $2.42 | $6,383.96 |
DisclosureSEC source: 0001649094-25-000039 · wk-form4_1741054462.xml · nonDerivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 02:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,270 | $73.02 | $92,735.40 |
DisclosureSEC source: 0001649094-25-000039 · wk-form4_1741054462.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,931 F3 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 02:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 2,869 | $73.02 | $209,494.38 |
DisclosureSEC source: 0001649094-25-000039 · wk-form4_1741054462.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,201 F3 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 02:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 5,649 | $73.02 | $412,489.98 |
DisclosureSEC source: 0001649094-25-000039 · wk-form4_1741054462.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,070 F2 · shares: Represents RSUs issued in lieu of a cash bonus by election of the Reporting Person, such election available to all of Issuer's senior management. The RSUs are fully vested upon the date of grant. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 72,536 | $0.00 Strike: $74.22 | $0.00 |
DisclosureSEC source: 0001649094-25-000039 · wk-form4_1741054462.xml · derivative · entry 10 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,536 Underlying: Common Stock · 72,536 shares Expires 2035-02-26 F7 · derivative.exercise_date: 1/48 of shares subject to the option vest on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 21,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-25-000039 · wk-form4_1741054462.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,421 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 7, 2025 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 00:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001649094-25-000010 · wk-form4_1738714793.xml · derivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,638 Underlying: Common Stock · 8,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option is fully vested and exercisable. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 00:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 20 | $87.94 | $1,758.80 |
DisclosureSEC source: 0001649094-25-000010 · wk-form4_1738714793.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,695 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 00:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,666 | $86.67 | $231,048.89 |
DisclosureSEC source: 0001649094-25-000010 · wk-form4_1738714793.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,715 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $86.365 to $87.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 00:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,314 | $86.00 | $456,982.74 |
DisclosureSEC source: 0001649094-25-000010 · wk-form4_1738714793.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,381 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $85.32 to $86.295. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 00:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $2.42 | $19,360.00 |
DisclosureSEC source: 0001649094-25-000010 · wk-form4_1738714793.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001649094-25-000002 · wk-form4_1735945636.xml · derivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,638 Underlying: Common Stock · 8,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,161 | $84.43 | $98,024.39 |
DisclosureSEC source: 0001649094-25-000002 · wk-form4_1735945636.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,695 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $84.315 to $84.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,483 | $83.69 | $458,861.30 |
DisclosureSEC source: 0001649094-25-000002 · wk-form4_1735945636.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,856 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $83.31 to $84.215. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,356 | $82.88 | $112,381.21 |
DisclosureSEC source: 0001649094-25-000002 · wk-form4_1735945636.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,339 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $82.31 to $83.265. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $2.42 | $19,360.00 |
DisclosureSEC source: 0001649094-25-000002 · wk-form4_1735945636.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2024 Filed Mar 4, 2025 02:13 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftCommon Stock | 74,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-25-000038 · wk-form4_1741054377.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,695 F1 · shares: Represents a transfer of ownership of the Issuer's common stock to a charitable remainder trust of which the Reporting Person is not a trustee. This transaction is being reported late due to a delay in receiving the transaction information from the Reporting Person's broker and is being reported promptly upon discovery. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 00:13 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001649094-24-000114 · wk-form4_1733271231.xml · derivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,638 Underlying: Common Stock · 8,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 00:13 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,127 | $94.06 | $106,007.87 |
DisclosureSEC source: 0001649094-24-000114 · wk-form4_1733271231.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,695 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $93.75 to $94.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 00:13 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,101 | $93.06 | $102,460.16 |
DisclosureSEC source: 0001649094-24-000114 · wk-form4_1733271231.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,822 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $92.70 to $93.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 00:13 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,772 | $92.07 | $531,416.50 |
DisclosureSEC source: 0001649094-24-000114 · wk-form4_1733271231.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,923 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $91.68 to $92.67. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 00:13 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $2.42 | $19,360.00 |
DisclosureSEC source: 0001649094-24-000114 · wk-form4_1733271231.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:48 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantPerformance Restricted Stock Units · Derivative | 35,661 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000107 · wk-form4_1731116900.xml · derivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,661 Underlying: Common Stock · 35,661 shares Expires 2034-11-06 F2 · derivative.exercise_date: Represents the target number of shares of Issuer's Common Stock underlying an award of performance restricted stock units ("PSUs"). Each PSU represents the contingent right to receive one share of the Issuer's Common Stock. The attainment of the performance vesting condition will be based on the Issuer's percentile rank within a peer group based on total shareholder return ("TSR") during a four-year performance period that commenced on November 7, 2024, the Grant Date, subject to the Reporting Person's continuous service with the Issuer through completion of the performance period. The actual number of shares of the Issuer's Common Stock deliverable with respect to the award varies based on performance and ranges from 0% to 250% of the target number of shares. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:48 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantPerformance Stock Option (right to buy) · Derivative | 87,481 | $0.00 Strike: $102.70 | $0.00 |
DisclosureSEC source: 0001649094-24-000107 · wk-form4_1731116900.xml · derivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,481 Underlying: Common Stock · 87,481 shares Expires 2034-11-06 F1 · derivative.exercise_date: As part of a company-wide grant to all eligible employees of the Issuer, on November 7, 2024 (the "Grant Date"), the Reporting Person was granted a performance stock option to purchase 87,481 shares of the Issuer's Common Stock at a per share exercise price of $102.70. The option is subject to (1) a service-based vesting condition (vesting as to one-third of the shares on each of the third, fourth and fifth anniversaries of the Grant Date) and (2) a performance-vesting condition (which generally requires that the trading price of the Issuer's Common Stock average, over a one-year period, is at least $154.05 (150% of the Grant Date closing price)). Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 23:45 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001649094-24-000090 · wk-form4_1730763923.xml · derivative · entry 6 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,638 Underlying: Common Stock · 8,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 23:45 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 240 | $108.93 | $26,143.20 |
DisclosureSEC source: 0001649094-24-000090 · wk-form4_1730763923.xml · nonDerivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,695 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 23:45 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 631 | $108.25 | $68,302.60 |
DisclosureSEC source: 0001649094-24-000090 · wk-form4_1730763923.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,935 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $107.86 to $108.505. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 23:45 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,174 | $107.20 | $233,057.15 |
DisclosureSEC source: 0001649094-24-000090 · wk-form4_1730763923.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,566 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $106.75 to $107.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 23:45 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,955 | $106.34 | $526,919.66 |
DisclosureSEC source: 0001649094-24-000090 · wk-form4_1730763923.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,740 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $105.75 to $106.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 23:45 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $2.42 | $19,360.00 |
DisclosureSEC source: 0001649094-24-000090 · wk-form4_1730763923.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 23:41 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,464 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001649094-24-000086 · wk-form4_1730245298.xml · derivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,876 Underlying: Common Stock · 3,464 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 23:41 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 1,585 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-24-000086 · wk-form4_1730245298.xml · derivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,026 Underlying: Common Stock · 1,585 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 23:41 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,464 | $20.93 | $72,501.52 |
DisclosureSEC source: 0001649094-24-000086 · wk-form4_1730245298.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares are subject to the restrictions on transfer set forth in a Lock-Up Agreement dated September 4, 2024. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 23:41 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 1,585 | $5.35 | $8,479.75 |
DisclosureSEC source: 0001649094-24-000086 · wk-form4_1730245298.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares are subject to the restrictions on transfer set forth in a Lock-Up Agreement dated September 4, 2024. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001649094-24-000076 · wk-form4_1727986596.xml · derivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,638 Underlying: Common Stock · 8,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,339 | $114.95 | $268,861.03 |
DisclosureSEC source: 0001649094-24-000076 · wk-form4_1727986596.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,646 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $114.81 to $115.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,349 | $114.32 | $382,840.94 |
DisclosureSEC source: 0001649094-24-000076 · wk-form4_1727986596.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,985 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $113.805 to $114.755. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,312 | $113.42 | $262,215.48 |
DisclosureSEC source: 0001649094-24-000076 · wk-form4_1727986596.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,334 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $112.805 to $113.78. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $2.42 | $19,360.00 |
DisclosureSEC source: 0001649094-24-000076 · wk-form4_1727986596.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 20:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001649094-24-000068 · wk-form4_1726691002.xml · derivative · entry 5 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,638 Underlying: Common Stock · 10,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 20:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 222 | $116.96 | $25,965.12 |
DisclosureSEC source: 0001649094-24-000068 · wk-form4_1726691002.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,646 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F4 · balance_after: The Reporting Person entered into a divorce settlement agreement with his ex-spouse (the "Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. On September 17, 2024, the Reporting Person transferred 1,312 shares of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 20:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,994 | $116.14 | $928,399.18 |
DisclosureSEC source: 0001649094-24-000068 · wk-form4_1726691002.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,180 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $115.715 to $116.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 20:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,784 | $115.06 | $205,270.61 |
DisclosureSEC source: 0001649094-24-000068 · wk-form4_1726691002.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,174 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $114.50 to $115.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 20:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 10,000 | $2.42 | $24,200.00 |
DisclosureSEC source: 0001649094-24-000068 · wk-form4_1726691002.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001649094-24-000066 · wk-form4_1725571164.xml · derivative · entry 12 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,638 Underlying: Common Stock · 10,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 5,545 | $110.15 | $610,781.75 |
DisclosureSEC source: 0001649094-24-000066 · wk-form4_1725571164.xml · nonDerivative · entry 11 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,958 F10 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated September 4, 2024 were sold by the Reporting Person. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 10 | $117.03 | $1,170.25 |
DisclosureSEC source: 0001649094-24-000066 · wk-form4_1725571164.xml · nonDerivative · entry 10 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,503 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,195 | $116.42 | $139,127.76 |
DisclosureSEC source: 0001649094-24-000066 · wk-form4_1725571164.xml · nonDerivative · entry 9 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,513 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F9 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $116.02 to $117.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 344 | $115.15 | $39,610.16 |
DisclosureSEC source: 0001649094-24-000066 · wk-form4_1725571164.xml · nonDerivative · entry 8 Wassil Jim · CIK 0001813798 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,708 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. F8 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $114.97 to $115.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.